24630-68-0

Basic information

• Product Name: DIISOPROPYL HYDROXYMETHYLPHOSPHONATE
• Synonyms: DIISOPROPYL HYDROXYMETHYLPHOSPHONATE;di(propan-2-yloxy)phosphorylmethanol
• CAS NO: 24630-68-0
• Molecular Formula: C₇H₁₇O₄P
• Molecular Weight: 196.18
• Mol File: 24630-68-0.mol

Chemical Properties

• Boiling Point: 261.6±23.0 °C(Predicted)
• Appearance: /
• Density: 1.094±0.06 g/cm3(Predicted)
• PKA: 12.87±0.10(Predicted)
• CAS DataBase Reference: DIISOPROPYL HYDROXYMETHYLPHOSPHONATE(CAS DataBase Reference)
• NIST Chemistry Reference: DIISOPROPYL HYDROXYMETHYLPHOSPHONATE(24630-68-0)
• EPA Substance Registry System: DIISOPROPYL HYDROXYMETHYLPHOSPHONATE(24630-68-0)

Safety Data

• Hazardous Substances Data: 24630-68-0(Hazardous Substances Data)

Usage

Uses

Used in Textile Industry:
Diisopropyl hydroxymethylphosphonate is used as a flame retardant and plasticizer in textiles, enhancing their resistance to fire and improving their flexibility and durability.
Used in Plastics Industry:
In the plastics industry, DIISOPROPYL HYDROXYMETHYLPHOSPHONATE serves as a plasticizer, which increases the pliability and workability of plastic materials, making them easier to process and use in various applications.
Used in Adhesives:
Diisopropyl hydroxymethylphosphonate is used as a flame retardant in adhesives to improve their fire safety properties, ensuring they do not easily ignite and contribute to the spread of fires.
Used as a Pesticide:
DIISOPROPYL HYDROXYMETHYLPHOSPHONATE is also utilized as an effective pesticide, helping to control a broad spectrum of insect pests, thereby protecting crops and enhancing agricultural productivity.
Overall, Diisopropyl hydroxymethylphosphonate is a valuable chemical with a wide range of applications across different industries, from enhancing the safety and quality of materials to providing effective pest control solutions.

Upstream product

• 50-00-0 formaldehyd 
• 1809-20-7 diisopropyl hydrogenphosphonate 
• 26955-63-5 diisopropyl methyl phosphate 
• 927267-66-1 diisopropyl (tributylstannyl)methyl phosphate 
• 110-71-4 1,2-dimethoxyethane 
• 691-96-3 diisopropyl phosphite 
• 116-17-6 triisopropyl phosphite 

Downstream Products

• 35717-98-7 bis(2-propyl)-p-toluenesulfonyloxymethylphosphonate 
• 143056-56-8 diisopropyl <<<4-(chloromethyl)benzyl>oxy>methyl>phosphonate 
• 203172-83-2 (diisopropylphosphonyl)methyl 3,5-bis-O-benzoyl-2-deoxy-β-D-erythro-pentofuranoside 
• 203172-82-1 (diisopropylphosphonyl)methyl 3,5-bis-O-benzoyl-2-deoxy-α-D-erythro-pentofuranoside 
• 203172-89-8 3-Trifluoromethyl-benzoic acid (2S,3R,4R,5R)-4-benzoyloxy-5-benzoyloxymethyl-2-(diisopropoxy-phosphorylmethoxy)-tetrahydro-furan-3-yl ester 
• 265322-97-2 (Z)-1-benzoxy-4-[((diisopropylphosphono)methoxy)methoxy]-2-butene 
• 143056-49-9 diisopropyl <<2-(chloromethyl)phenoxy>methyl>phosphonate 
• 143056-48-8 diisopropyl <<2-(hydroxymethyl)phenoxy>methyl>phosphonate 
• 143056-68-2 diisopropyl <<2-<(2-amino-6-chloro-9H-purin-9-yl)methyl>phenoxy>methyl>phosphonate 
• 143056-73-9 diisopropyl <<<4-<(2-amino-6-chloro-9H-purin-9-yl)methyl>benzyl>oxy>methyl>phosphonate 
• 143056-70-6 diisopropyl <<<2-<(2-amino-6-chloro-9H-purin-9-yl)methyl>benzyl>oxy>methyl>phosphonate 
• 143056-69-3 diisopropyl <<<3-<(2-amino-6-chloro-9H-purin-9-yl)methyl>benzyl>oxy>methyl>phosphonate 
• 1023289-21-5 diisopropyl (4-nitrobenzenesulfonyloxy)methylphosphonate 

Relevant articles and documents

Chemoenzymatic Synthesis of Racemic and Enantiomerically Pure Phosphaaspartic Acid and Phosphaarginine

Diisopropyl allyloxymethylphosphonate prepared by a one-pot procedure was isomerized to give racemic 1-hydroxy-3-butenylphosphonate with LDA by a [2,3]-sigmatropic rearrangement. Chloroacetylation delivered an ester, which was resolved in a two-phase system by using the lipase from Thermomyces lanuginosus. Racemic and (S)-α-hydroxyphosphonate 6 were converted to (±)- and (R)-phosphaaspartic acid by functional-group manipulation. (±)-, (R)- and (S)-6 were first esterified with 4-nitrobenzenesulfonyl chloride before hydroboration to transform the double bond into a hydroxyethyl group. The hydroxyl group was manipulated to give a guanidinyl group and the 4-nitrobenzenesulfonyloxy to give an amino group. Global deprotection of the α-aminophosphonates yielded the desired phosphaamino acids.

PHOSPHONATE CONJUGATES AND USES THEREOF

Phosphonate conjugates, preferably, bisphosphonate conjugates; methods of inhibiting Ron receptor tyrosine kinase and methods of treatment of bone destruction due to cancer or other conditions utilizing the provided phosphonate conjugates.

THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF

A thyroid hormone receptor agonist and its use in the treatment of a disease associated thyroid hormone receptor beta are described. The compound can be effective in lowering cholesterol with minimum or no adverse effects on the heart or thyroid hormone axis.

NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS

The present invention relates to novel pro-drugs of L-2'-deoxythreose nucleoside phosphonates, such as phosphoramidate, phosphorodiamidate and phospho-diester prodrugs. The invention also relates to a process for preparing these novel prodrugs of nucleoside phosphonates. The invention also relates to the use of these novel phosphonatemodified nucleosides to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with viruses belonging to the HBV family.

Copper-catalyzed synthesis of α-hydroxy phosphonates from H-phosphonates and alcohols or ethers

Easy PC: α-Hydroxy phosphonates were synthesized by copper/tert-butyl hydroperoxide (TBHP)-catalyzed oxidative addition reactions of H-phosphonates with alcohols or ethers. Diverse α-hydroxy phosphonates were obtained from substituted benzyl alcohols or alkyl alcohols and alkyl ethers in moderate to good yields. Copyright

GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS

This invention relates to compounds useful for inhibiting telomere elongation. More specifically, the invention provides nucleotide analogs that are incorporated into telomeres by telomerase thereby inhibiting elongation of telomeres. The compounds are useful in treating cancer and other cell proliferative diseases.

PHOSPHORUS-CONTAINING THYROID HORMONE RECEPTOR AGONISTS AND METHODS OF USE

The present invention relates to sulfonic acid containing compounds that bind to thyroid receptors in the liver. Activation of these receptors results in modulation of gene expression of genes regulated by thyroid hormones. The compounds can be used to treat diseases and disorders including metabolic diseases such as NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, and metabolic syndrome X.

Synthesis of cyclopropane-containing phosphorus compounds by radical coupling of butenylindium with iodo phosphorus compounds

The radical coupling of α- or β-iodo phosphorus compounds such as iodo phosphonate, iodo phosphane oxide, and iodo phosphonothioate with butenylindium species, prepared by transmetalation between a (cyclopropylmethyl)stannane and InBr3, afforded the corresponding cyclopropylmethylated products. The radical reaction was initiated by the radical species generated from butenylindium assisted by a small amount of oxygen. Butenylindium works not only as a cyclopropylmethylating reagent, but also as a radical initiator. For successful coupling, a tin/indium transmetalation was used, where it was important for the tin halide by-product to be inert to the reaction system. In addition, the transmetalation of a (cyclopropylmethyl)stannane and InBr3 provided the dibutenylindium bromide as a single product, which smoothly coupled with the unstable phosphonyl radical species from the iodo phosphorus compound. A photochemical method (UV irradiation) was also applied and accelerated the coupling reaction. The cyclopropylmethylated phosphonate produced was a good intermediate in the Horner-Wadsworth-Emmons reaction and gave functionalized olefins bearing the cyclopropane moiety. Copyright

Preparation of chiral α-oxy-[2H1]methyllithiums of 99% ee and determination of their configurational stability

(Tributylstannyl)methyl 2,2,6,6-tetramethylpiperidine-1-carboxylate was metalated with t-BuLi/TMEDA at -78 °C and borylated with the mixed borate derived from (R,R)-1,2-dicyclohexylethane-1,2-diol and t-butanol to give diastereomeric boronates 31/32 in equal amounts. Boronates 31 and 32 were reduced with LiBEt3D and then oxidized with basic H2O 2 to give (S)- and (R)-tributylstannyl-[1-2H 2]methanol of 99% ee, respectively. Treatment of their respective phosphates with n-BuLi at -78 and 0 °C gave microscopically configurationally stable phosphinyloxy-substituted [2H 1]methyllithiums, which rearranged to hydroxy-[1-2H 1]-methylphosphonates of ee > 98% (phosphate-phosphonate rearrangement). The N,N-iisopropylcarbamates of the enantiomeric tributylstannyl-[1-2H1]methanols were transmetalated to give carbamoyloxy-substituted chiral [2H1]methyllithiums, which were macroscopically configurationally stable for prolonged periods of time (up to 3 h, ee still 99%) at -78 °C, deduced from trapping experiments with benzaldehyde. The chemical stability of these methyllithiums ended at -50 °C. The stereochemistry of the monoprotected and monodeuterated 1-phenylethane-1,2-diols obtained was secured by spectroscopic comparison of their Mosher esters with that of all four stereoisomeric 1-phenyl-[1- 2H1]ethane-1,2-diols synthesized independently. Furthermore, the configurations of the boronates and the chiral methyllithiums derived from them were deduced from a single-crystal X-ray structure analysis of a carbamate in which the tributylstannyl group had been replaced by the [(1R)-menthyl]dimethylstannyl group.

NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT

The present invention provides novel compounds with activity against infectious viruses. The compounds of the invention may inhibit retroviral reverse transcriptases and thus inhibit the replication of the virus. They are useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-1 or HIV-2) or human T-cell leukemia viruses (HTLV-I or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and/or related diseases. The present invention also relates generally to the accumulation or retention of therapeutic compounds inside cells. The invention is more particularly related to attaining high concentrations of active metabolite molecules in HIV infected cells. Intracellular targeting may be achieved by methods and compositions which allow accumulation or retention of biologically active agents inside cells. Such effective targeting may be applicable to a variety of therapeutic formulations and procedures.